NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3032% below fair value
$10.71+0.02 (+0.19%)
Close on Nov 20, 2026Market cap $1.25BP/E –Yield –
NovoCure free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
NovoCure's free cash flow for the twelve months ending Sep 30, 2026 was -$24.61M. For fiscal 2025 it was -$75.68M. The highest annual figure on record is $84.18M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$75.68M | – |
| FY2024 | Dec 31, 2024 | -$69.22M | – |
| FY2023 | Dec 31, 2023 | -$100.43M | -1165.0% |
| FY2022 | Dec 31, 2022 | $9.43M | -83.9% |
| FY2021 | Dec 31, 2021 | $58.59M | -30.4% |
| FY2020 | Dec 31, 2020 | $84.18M | +421.7% |
| FY2019 | Dec 31, 2019 | $16.14M | – |
| FY2018 | Dec 31, 2018 | -$8.58M | – |
| FY2017 | Dec 31, 2017 | -$40.50M | – |
| FY2016 | Dec 31, 2016 | -$113.27M | – |
| FY2015 | Dec 31, 2015 | -$104.55M | – |
| FY2014 | Dec 31, 2014 | -$75.09M | – |
| FY2013 | Dec 31, 2013 | -$54.92M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $15.75M | +5.5% |
| Q2 FY2026 | Jun 30, 2026 | $1.22M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.67M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.90M | – |
| Q3 FY2025 | Sep 30, 2025 | $14.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$46.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.39M | – |
| Q3 FY2024 | Sep 30, 2024 | -$307.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$43.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$26.57M | -258.9% |
| Q2 FY2023 | Jun 30, 2023 | -$29.67M | -355.1% |
| Q1 FY2023 | Mar 31, 2023 | -$22.82M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.14M | -7898.5% |
| Q3 FY2022 | Sep 30, 2022 | $16.72M | -20.8% |
| Q2 FY2022 | Jun 30, 2022 | $11.63M | -50.6% |
| Q1 FY2022 | Mar 31, 2022 | -$8.78M | -163.6% |
| Q4 FY2021 | Dec 31, 2021 | $130.00K | -99.7% |
| Q3 FY2021 | Sep 30, 2021 | $21.10M | -25.1% |
| Q2 FY2021 | Jun 30, 2021 | $23.55M | +149.9% |
| Q1 FY2021 | Mar 31, 2021 | $13.80M | – |
| Q4 FY2020 | Dec 31, 2020 | $47.72M | +1121.4% |
| Q3 FY2020 | Sep 30, 2020 | $28.19M | +131.1% |
| Q2 FY2020 | Jun 30, 2020 | $9.43M | +41.3% |
| Q1 FY2020 | Mar 31, 2020 | -$1.16M | – |
| Q4 FY2019 | Dec 31, 2019 | $3.91M | -74.0% |
| Q3 FY2019 | Sep 30, 2019 | $12.20M | +184.7% |
| Q2 FY2019 | Jun 30, 2019 | $6.67M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.64M | – |
| Q4 FY2018 | Dec 31, 2018 | $15.02M | – |
| Q3 FY2018 | Sep 30, 2018 | $4.29M | +113.9% |
| Q2 FY2018 | Jun 30, 2018 | -$8.35M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.56M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.31M | – |
| Q3 FY2017 | Sep 30, 2017 | $2.00M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.25M | – |
| Q1 FY2017 | Mar 31, 2017 | -$27.94M | – |
| Q4 FY2016 | Dec 31, 2016 | -$14.34M | – |
See a number that looks wrong?